Mainz Biomed

Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

BERKELEY, Calif. and MAINZ, Germany, March 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, in collaboration with Ganzimmun, will host an educational webinar on Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options which is taking place on March 20, 2024.

Designed for pharmacists, physicians, and healthcare professionals, this online training session aims to shed light on innovative laboratory diagnostic approaches for colorectal cancer screening. Set against the backdrop of March's Colorectal Cancer Awareness Month, the webinar will delve into the significance of genetic markers and the advancements in screening techniques that offer a more accurate risk assessment and early detection. Attendees will have the opportunity to earn continuing education credits, with two certification points from ÄK and one from BDH.

Event Details:

• Educational Webinar for medical community in German language
• Title: Darmkrebs-Früherkennung: Neue labordiagnostische Optionen (Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options)
• Speaker: Jürgen Fuhrländer, Senior Consultant Medical Sciences
• Certification: 2 ÄK points, 1 BDH point
• Target Audience: Pharmacists, Physicians, Healthcare Professionals
• Hosts: MainzBiomed, Ganzimmun
• Date: March 20, 2024
• Time: from 07:00 PM to 08:15 PM (CET)
• Location: Online
• Cost: Free

For more information and to register, please visit Mainz Biomed's official website or https://www.ganzimmun.de/service/akademie/fortbildungskalender?event_u ....

Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information.

Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook

About ColoAlert
ColoAlert, Mainz Biomed’s flagship product, delivers high sensitivity and specificity in a user-friendly, at-home colorectal cancer (CRC) screening kit. This non-invasive test can be indicative of tumors as determined by analyzing tumor DNA, offering better early detection than fecal occult blood tests (FOBT). Based on PCR-technology, ColoAlert detects more cases of colorectal cancer than other stool tests and allows for an earlier diagnosis (Dollinger et al., 2018). The product is commercially available in select EU countries through a network of leading independent laboratories, corporate health programs and via direct sales. To receive marketing approval in the US, ColoAlert will be evaluated in the FDA-registration trial ‘ReconAAsense.’ Once approved in the US, the Company’s commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country.